Basecamp Vascular (BCV) has announced the appointment of Thierry Col as its new CEO, effective 1 February 2023.
He succeeds interventional neuroradiologist Raphaël Blanc (Foundation Rothschild Hospital, Paris, France), the company’s co-founder and president, who has held this role since the creation of BCV in 2016.
Blanc will continue as president of BCV in order to bring the start-up—of which he is one of four co-founders alongside Jean-Baptiste Cazeneuve, Michel Boulaire and Jérôme Szewczyk—to a crucial phase of its development. However, he is now set to hand over the operational part of the company to Col.
Col’s career has spanned several continents (Europe, the Middle East, Africa, Asia and North America) as well as a variety of fields, from high technology to healthcare, and includes more than 20 years of experience in mature and emerging international MedTech markets—most recently at Corza Medical.
He has described this new project as “a human adventure as well as an entrepreneurial experience”.
Col joins the BCV team, where he will actively take care of its fundraising, the CE marking of its first-generation device, its international expansion—including with US Food and Drug Administration (FDA) approval for the USA—its industrialisation, and its research and development through the Gecko+ project.